|
System used
|
RNS
|
CorPath 200
|
CorPath 200
|
CorPath GRX
|
CorPath GRX
|
R-One
|
|
Number of sites, n
|
1
|
9
|
n/r
|
1
|
20
|
6
|
|
Patients, n
|
18
|
164
|
108
|
40
|
980
|
62
|
|
Complex lesions, %
|
n/r
|
31.7
|
78.3
|
77.8
|
68.8
|
25.0
|
|
Technical success, %
|
83.3
|
98.8
|
91.7
|
90.0
|
86.5
|
95.2
|
|
Clinical success, %
|
100
|
97.6
|
99.1
|
97.5
|
97.8
|
100
|
|
MACE, % (follow-up)
|
0 (in-hospital)
|
0 (30 days)
|
0.9 (in-hospital)
|
n/r
|
0 (in-hospital)
|
0 (30 days)
|
|
Total procedure time, min
|
44
|
n/r
|
44.5
|
40.2
|
54.3
|
39.9
|
|
Total robotic procedure time, min
|
n/r
|
24.4
|
n/r
|
n/r
|
n/r
|
19.9
|
|
Mean fluoroscopy time, min
|
8.8
|
11.1
|
18.2
|
17.4
|
17.8
|
10.3
|
|
Mean contrast injection volume, mL
|
n/r
|
144.2
|
183.4
|
171
|
118.2
|
118.3
|
|
Mean patient radiation exposure, mGy
|
n/r
|
1,500
|
n/r
|
n/r
|
n/r
|
540.3
|
|
Mean reduction in operator radiation exposure with lead protection, %
|
n/r
|
n/r
|
n/r
|
n/r
|
n/r
|
84.5
|
|
Median reduction in operator radiation exposure, %
|
n/r
|
95.2
|
n/r
|
n/r
|
n/r
|
100 (under lead)
86.07 (on lead)
|
|
*(Medranda GA, Waksman R. Safety and Efficacy of the Second-Generation Robotic Assisted Systems for PCI. Society for Cardiovascular Angiography and Interventions. 2 July 2021; https://scai.org/safety-and-efficacy-second-generation-robotic-assisted-systems-pci-coverage-late-breaking-science. [Last accessed 7 Dec 2022]). MACE: major adverse cardiac event; mGy: milligray; n/r: not reported; RNS: remote navigation system
|
